Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

NPJ Breast Cancer · 2025 · PMC12480687 · PMID 41022779

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

a trend toward significancep = 0.052so close (0.05 < p ≤ 0.1)

Moreover, when testing the interaction between MHC-II status using this cutoff and treatment arm on pCR, we observed a trend toward significance ( p = 0.052) (Fig. 1B ).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.